Podcasts about CRISPR

This edition of The Neil Haley Show opens with actor and comedian Ken Jeong, who called this the greatest year of his career as his ABC series Dr. Ken wrapped its final episode. Jeong, known to fans from Community and The Hangover, described the joy of building a family comedy rooted in his own life as a doctor and father of twin daughters, and of bringing back friends and comedy heroes like his Community co-stars and Jeffrey Ross as guests. He highlighted a favorite Ken-and-Molly episode in which his character takes his daughter, played by Krista Marie Yu, and her friends to an Emblem3 concert to reconnect with a girl he feels slipping away, alongside a subplot involving Pat and Damona, played by Dave Foley and Tisha Campbell-Martin. Jeong and Neil traded thoughts on how fathers instinctively struggle to relate to daughters and the male urge to fix everything, and Jeong noted that unlike his self-aware real self, his character Ken Park has no self-awareness at all, which is where the comedy lives.Neil then welcomed Harvard physician and author Dr. Robert J. McCunney to discuss his medical thriller The Aging Code. McCunney explained that he builds his novels around topics he wants to learn more about, in this case the science of aging, gene therapy and CRISPR, and the Russian-Ukrainian conflict, weaving them through a health journalist, a United Nations clinic physician, and a Russian emigre genetic scientist. He walked Neil through genuinely striking research: medications like rapamycin extending the lifespan of lab mice by thirty to fifty percent, the rare genetic condition progeria that accelerates aging through a single DNA mutation, and gene-therapy work involving the protein klotho. He drew a careful distinction between life expectancy, a statistical average, and lifespan, which he said is now truly increasing for the first time since Roman times, and cautioned about the real dangers of unproven biohacking, since a drug that suppresses the immune system carries serious risk without careful dosing and long-term study. Citing Harvard geneticist David Sinclair's view that aging itself might be treated as a disease, McCunney, who is seventy-eight and still sees patients, offered his own credo: take risks, don't chase money, and love what you do.The program continues with a Jesus and Ugly Jodi simulcast featuring Jodi Corbett, who introduced Five Stones Ministry, a new church based in Longboat Key, Florida, with a global online presence holding its very first service. Corbett explained the name from David choosing five smooth stones to face Goliath, and described a church built to complement rather than replace people's local Sunday congregations. Its flagship effort is a Widows' Fund, guided by 1 Timothy 5, to help pastors' and missionaries' widows with mortgages and other financial burdens while affirming their ongoing value and gifts. He also outlined Peacemaker Security, drawn from his years in law enforcement and the FBI, which aims to reduce violence and eliminate homicides by hiring people from within troubled communities, along with planned ministries in pastoral care and orphan support.The show closes with a Storehouse Media Group simulcast featuring Cheryl Lovell, founder of CLC Group. A Navy veteran of the Gulf War who pivoted from nursing into healthcare administration, Lovell built and sold her own home health, hospice, and palliative care companies before moving into consulting.

Bryant Williams, founder of Nurtured Nuts, discusses how gene-editing technology could transform peanut allergy prevention and expand safe food choices for millions of consumers. Nurtured Nuts is commercializing the world’s first allergen-less peanut butter developed using advanced CRISPR technology. AgriNetica is the developer and owner of the technology underlying the hypoallergenic peanuts. Also in this episode, a special segment from IFT FIRST's Hot Topic Studio on snealing (i.e., blending meals and snacks into mini, functional eating occasions) and how brands are responding to consumer demand with nutrient-dense, portable, satiety-boosting products in traditional daypart categories. Plus: This episode of Omnivore is brought to you by RTI International, an independent scientific research institute dedicated to improving the human condition. Discover more at RTI.org/food-innovation.

TWiV explains discovery of a previously unknown mechanism of RNA-guided DNA recognition for genetic control that possibly predates the emergence of CRISPR pathways, and the possibility that Alzheimer's Disease neuropathology evolved as a host defense response to microbial infection in the brain. Hosts: Vincent Racaniello, Alan Dove, and Brianne Barker Subscribe (free): Apple Podcasts, RSS, email Become a patron of TWiV! Links for this episode Support science education at MicrobeTV Bob Tesh dies (Galv News) Comment on propsed changes to NIH peer review (NIH) NIH peer review proposed changes (Forbes) Ancient RNA guided DNA recognition (Science) Noncontiguous geometric triplex (Science) p-tau has anti-herpes virus activity (Nat Neurosci) Letters read on TWiV 1361 Timestamps by Jolene Ramsey. Thanks! Picks of the Week Brianne – APoD September 14: Origins of Elements Alan – Redshirts, by John Scalzi Vincent – Prone to Bruise by David Molesky he's at Spring/Break till 9/28 Listener Pick Anne – Nikon Small World in Motion Competition Intro music is by Ronald Jenkees Send your virology questions and comments to twiv@microbe.tv Content in this podcast should not be construed as medical advice.

El el futuro tendremos el dilema se intervenir en el ADN con el sistema CRISPR, el llamado corta-pega genético. Ya estamos viendo sus primeros efectos, pero es sólo el comienzo de una nueva era en la que la genética cambiará el mundo.

Trump hosts Xi at the White House, Iran's Pezeshkian tells the U.N. his country is the "victim of terrorism," OpenAI agents breach an Australian Medicare portal, the White House reportedly considers a 90-day diesel export ban, a judge orders the White House to restore three outlets' press passes, Venezuela's Rodríguez promises elections will be held at the "right moment," Poland probes a fire at its Starlink station as a possible act of sabotage, FDA nominee Overton faces Senate questioning, Claude discovers a CRISPR-like enzyme system, and Bentley launches its first all-electric car. Sources: Verity.News

Meta unveiled $1,299 VR Glasses, $349 camera-free Ray-Ban Audio glasses, and a keychain Muse Charm gadget, plus Ray-Ban Display upgrades. Anthropic's Claude agents found a CRISPR-like enzyme system in its biolab. OpenAI's agents hacked an Australian government site hunting data. Meta debuts Meta VR Glasses, a ~100g VR headset with an external compute pack, three-hour battery, and ~2.5K resolution per eye, coming spring 2027 for $1,299 (Bloomberg) The Verge goes hands-on with the Meta VR Glasses, calling them a lighter, easier-to-live-with take on Vision Pro-style computing — from VR-enhanced Avengers screenings to a surprisingly usable virtual keyboard (The Verge) Meta unveils Ray-Ban Meta Audio, its first pair of glasses without cameras, offering up to 12 hours of battery life, starting at $349 and shipping October 13 (Bloomberg) Meta Ray-Ban Display glasses add holographic-avatar video calls, voice-guided transit directions, and a new Explore app for finding compatible programs (Engadget) Meta previews Muse Charm, a palm-sized Tamagotchi-like device for using Muse, with a ~2" OLED screen, front and rear cameras, and 5G, on sale by the end of 2026 (Bloomberg) Meta's Muse Charm houses a cute digital avatar named Jolly and lets you start talking to Muse with a tap of the fingerprint sensor — no phone unlock required (TechCrunch) Muse agents are getting their own email addresses, a live video-call mode, and the ability to control your Mac (The Verge) Anthropic's biolab made a discovery it's comparing to Crispr (The Verge) OpenAI agents hacked an Australian government website in search for data (The New York Times) Subscribe to the ad-free feed.

Russell has spent a day and a half with Instinct, an invite-only AI agent that lives in iMessage. It logged into a platform on its own, pulled the confirmation code from his email, and finished the job in about a minute. That is the promise of the AI agent in a box. The price is access to your data. From there, the news: Meta testing human contractors behind its Muse agent's phone calls, Verizon's $70 million AI training push after 13,000 job cuts, an OpenAI agent that reached into an Australian government health portal, YouTube's new AI creator tools, and Anthropic's CRISPR-like enzyme discovery. The through line: keep AI in your loop, not you in its loop.About the showJudgment Call is live every weekday morning. Every weekday, Russell Fugett thinks out loud about the decisions AI can't make for you. He's an entrepreneur, AI strategist, solutions architect, and a man of faith who builds real things with AI and talks plainly about the judgment behind them. No script. Five minutes or an hour, sometimes live from wherever he is. As the show grows, guests will start dropping in.Missing phone calls means missing revenue. Get Joe, the AI voice agent who's always on call. Visit https://fugettlabs.com to learn more.Have a bigger AI question for your business? Book a free AI Opportunity Discovery Call: https://audit.fugettlabs.comWant to be a guest, or have a thought to add? https://fugettlabs.com/aboutFugett Labs: https://fugettlabs.comRussell Fugett: https://russellfugett.comFollow @russellfugettLinkedIn: https://www.linkedin.com/in/jrussellfugett/YouTube: https://www.youtube.com/@russellfugettInstagram: https://www.instagram.com/russellfugettTools I use (affiliate links; I may earn a commission if you sign up)Claude: https://claude.ai/referral/cC2wZqegHwWispr Flow: https://wisprflow.ai/r?J22272Lovable: https://lovable.dev/invite/KLWQBULBetterHelp (online therapy): https://www.betterhelp.com/rpc/f28c16d729eb10d8-5-01?utm_term=ref_v2_ddPodMatch (find podcast guests and shows): https://www.joinpodmatch.com/russellfugettGoFractional (find executive-level fractional work or fractional talent): https://www.gofractional.com/r/j-russell-fugett

David Sánchez mantiene una llamada con el servicio de atención al cliente de Apple a raíz de sus quejas en redes sociales por un fallo en la garantía de su teléfono. Desde la empresa le piden que cese sus comentarios negativos y le ofrecen devolver los dispositivos a cambio de una compensación económica. Por otra parte, el equipo de El Partidazo de COPE prepara su próxima emisión en directo desde Málaga y resalta el éxito de la gira de La Oreja de Van Gogh, que agota las entradas en Madrid. Carlos Moreno "El Pulpo" inicia el programa nocturno Poniendo las calles para acompañar a la audiencia de madrugada. En este espacio interviene Pablo Bermejo, doctor en veterinaria y experto en ingeniería genómica, quien explica la modificación del ADN de animales mediante la tecnología CRISPR. El investigador detalla cómo se eliminan en etapas embrionarias las proteínas caninas que provocan alergia a las personas. Además, analiza los tiempos que requiere este procedimiento científico, sus ...

The Daily Business and Finance Show - Thursday, 24 September 2026 We get our business and finance news from Seeking Alpha and you should too! Subscribe to Seeking Alpha Premium for more in-depth market news and help support this podcast. Free for 14-days! Please click here for more info: Subscribe to Seeking Alpha Premium News Today's headlines: Gene editing stocks fall after Anthropic's CRISPR-like discovery F-35 parts with stealth coating diverted to Hong Kong, taken by China New bill seeks to give first-time homebuyers up to $50K Judge lifts Trump's White House ban on CNN, MS NOW, Politico: report 3 things to look out for on Thursday SpaceX president Shotwell files to sell nearly $52M in stock Big oil mobilizes to block Trump's diesel export ban idea: WSJ Stock futures lower after Wall Street selloff Explanations from OpenAI ChatGPT API with proprietary prompts. This podcast provides information only and should not be construed as financial or business advice. This podcast is produced by Klassic Studios Learn more about your ad choices. Visit megaphone.fm/adchoices

Broadcast from KSQD, Santa Cruz on 9-17-2026: Dr. Dawn opens with a primer on kidney function: their embryonic origin adjacent to the gonads, their central role in blood pressure regulation (retaining fluid in hemorrhage but paradoxically worsening heart failure), erythropoietin production (both an athletic doping agent and a mechanism by which severe sleep apnea can cause stroke-risk polycythemia), acid-base balance via bicarbonate, and nitrogen waste removal including uric acid. The U.S. waiting list holds 95,492 people needing kidney transplants—88% of all organ waitlist patients—against only 27,500 annual donations, with 12-13 people dying daily on the list. Dr. Dawn walks through a Wired magazine analysis of paid donation, noting Iran is the only country with a legal regulated kidney market (Iranian citizens only, with a waiting list of donors and compensation around two months of median income). She frames the ethical debate: current U.S. altruistic donation implicitly rewards those with money and social networks who can afford time off, while poorer populations bear disproportionate end-stage renal disease burden. Proposed compensation alternatives include lifetime congressional-quality health insurance, student loan forgiveness, six-month waiting periods for informed consent, and 20-year payout structures. Donation mortality risk is comparable to childbirth—several-fold lower than logging. Tim Andrews became the first patient to receive a genetically modified pig kidney as a bridge to human transplant, sustaining him 271 days until a human kidney became available (the pig kidney ultimately lost to pyelonephritis, not rejection). eGenesis used CRISPR to delete three highly antigenic pig genes—GGTA1 (which produces alpha-gal, the tick-transmitted meat allergy trigger), CMAH, and one other—along with porcine endogenous retroviruses, and added seven human genes for coagulation compatibility and anti-inflammation. Dr. Dawn notes the animal welfare implications of farming 50,000 modified pigs annually and unknown long-term graft survival. An emailer asks about direct-to-consumer full-body MRI screening. Dr. Dawn explains MRI's advantages (no ionizing radiation, no kidney-toxic contrast) but emphasizes false positive harms: indeterminate findings that require invasive follow-up biopsies for lesions unlikely to be lethal, and the psychological burden of "ghost" diagnoses. Whole-body MRI also poorly evaluates lungs, intestines, and breasts (different scan parameters required). She recommends full-body MRI only for high-risk cancer predisposition syndromes like Lynch syndrome, BRCA 1/2, and Li-Fraumeni. Dr. Dawn debunks the "seed" model of probiotic capsules: strains taken for six months typically disappear from the gut within a month of stopping. Much of probiotic benefit comes from dead bacteria—autoclaved cell walls remain biologically active with antibacterial effects. Her clinical protocol uses 200-300 billion CFU four times daily to treat traveler's diarrhea, avoiding Cipro's tendon toxicity. For antibiotic-associated C. difficile prevention, Saccharomyces boulardii plus Bifidobacterium and Lactobacillus have double-blind placebo-controlled support when taken between antibiotic doses and for a week afterward. A caller with type 2 diabetes describes suspected treatment-induced neuropathy following rapid A1c reduction from 10.2 to a GMI of 5.8. She has burning, electric tingling, and unexplained deep muscle-soreness sensations, mostly proximal in the left leg with recent right-leg involvement, and pregabalin isn't helping. Dr. Dawn distinguishes small-fiber neuropathy (temperature-related, patchy, requires skin biopsy for diagnosis—EMG and nerve conduction won't show it) from large-fiber neuropathy (symmetric, ascending from toes). The proximal top-down distribution suggests small-fiber involvement. She recommends functional-medicine adjuncts: methylated B12 2,000 mcg, methylated folate 2,000 mcg, and alpha-lipoic acid 300 mg twice daily for three months. She also recommends a provoked heavy-metals urine test to rule out copper or other neurotoxic exposure. Dr. Dawn closes with the fiber recommendation of 14 grams per 1,000 calories (correcting an earlier misstatement of 14g total per day) and emphasizes that a diverse plant-based diet—fruits, vegetables, root vegetables, beans, nuts—does more for microbiome health than any capsule.

Scientists in Australia are using CRISPR technology, which allows them to edit out specific genes to open up the treatment options for people with blood cancer. Professor Marco Herold and his team at the Olivia Newton-John Cancer Research Institute have been focused on helping patients who're resistant to lymphoma drugs, and now, they think they've achieved something that could help alleviate the lives of millions of people.

Genetic medicine has already begun to transform the treatment of some inherited diseases, but the brain remains one of its most formidable frontiers. For disorders such as Huntington's disease and ALS, scientists may understand key genetic contributors and have increasingly powerful editing tools, yet getting those tools safely, efficiently, and selectively into vulnerable neurons is another matter entirely. Evox Therapeutics is developing an approach built around naturally occurring nanoparticles that cells use to communicate, known as exosomes, as delivery vehicles for CRISPR-based medicines. We spoke with Per Lundin, the company's co-founder and CEO, about the promise and limitations of exosome-enabled gene editing, how the company is prioritizing its pipeline, and what it will take to establish this emerging therapeutic strategy in the clinic.

Existe uma corrida acontecendo no mundo. Ela não está nas pistas. Está nos laboratórios. E quem chegar primeiro pode ajudar a definir como vamos produzir alimentos nas próximas décadas. Estamos falando de editar genes com precisão. Desenvolver plantas mais preparadas para enfrentar doenças e estresses. Aumentar a vida útil dos alimentos. Criar novas soluções para controlar pragas. E fazer em semanas aquilo que, em determinados processos, poderia consumir anos de melhoramento. Esse avanço abre um leque ainda maior: durante muito tempo, colocar uma inovação biotecnológica no mercado exigiu investimentos tão altos que poucas empresas tinham condições de participar desse jogo. Agora, esse cenário começa a mudar. É a “democratização da biotecnologia”, segundo o nosso convidado deste episódio. Pesquisador da Embrapa há 36 anos e membro da CTNBio por dez mandatos, Alexandre Nepomuceno viu a transgenia chegar, acompanhou suas polêmicas e hoje presencia uma nova geração de tecnologias abrir possibilidades que pareciam improváveis. Inclusive para pequenos grupos de pesquisadores e startups brasileiras. Enquanto o mundo discute inteligência artificial e revolução digital, ele chama atenção para outra transformação que avança quase silenciosamente (para a maioria das pessoas): a revolução genética, impulsionada por tecnologias como edição gênica, CRISPR, RNA interferente, capazes de acelerar caminhos que o melhoramento convencional poderia levar muitos anos para percorrer. É uma corrida na qual o Brasil tem agricultura, conhecimento e gente preparada para competir. Mas será que estamos investindo o suficiente? Afinal, formar cientistas brilhantes e não criar espaço para transformar conhecimento em inovação também pode significar ver esse futuro sendo construído em outros países. Neste episódio, ciência de ponta vira conversa de porteira aberta. Sem complicação. Com exemplos que impressionam. E com uma provocação que interessa a todo o agro brasileiro: quem vai desenvolver as tecnologias que vão produzir o alimento do futuro?See omnystudio.com/listener for privacy information.

Sickle cell disease has long been a frustrating medical condition impacting a historically overlooked patient population, but now there is something of a medical miracle treatment available.If only it were that simple.An estimated 100,000 Americans live with sickle cell disease, which disproportionately affects people of African descent. Roughly one in every 365 Black births in the U.S. is affected.In recognition of National Sickle Cell Awareness Month, Dr. Alana Arnold, a pediatric emergency physician and healthcare executive, and Akinwole Garrett, CEO of BlackDoctor, are on the podcast to discuss the systemic changes needed to improve patient outcomes.Editor-at-large Steve Madden helms a dual interview exploring the latest advancements in sickle cell disease treatment – namely the breakthrough CRISPR therapy Casgevy – as well as what has kept a medical miracle trapped behind systemic barriers.Arnold and Garrett hone in on the challenges of healthcare disparities and the systemic changes needed to improve outcomes in this particular patient community.For Trends, Madden and executive editor Jack O'Brien talk with reporter Bella Czajkowski about Novo Nordisk's rebrand to “Novo” and how the Danish pharma giant can make the most of this moment for a cultural reset. Check us out at: mmm-online.com Follow us: YouTube: @MMM-onlineTikTok: @MMMnewsInstagram: @MMMnewsonlineTwitter/X: @MMMnewsLinkedIn: MM+M To read more of the most timely, balanced and original reporting in medical marketing, subscribe here.Music: “Deep Reflection” by DP and Triple Scoop Music. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. In today's episode, we're diving into a series of breakthroughs and significant updates that are shaping the landscape of medicine and treatment. Let's start with a remarkable development in the realm of personalized medicine. Researchers have announced a breakthrough in gene-editing technology that holds promise for treating a range of genetic disorders. This new technique, which builds upon CRISPR technology, allows for more precise editing of DNA, minimizing off-target effects that have been a concern in earlier methods. By improving the accuracy of gene editing, this advancement could potentially pave the way for safer and more effective therapies for conditions like cystic fibrosis and sickle cell anemia. The significance of this development cannot be understated, as it represents another step forward in the quest to tailor medical treatments to individual patients' genetic profiles. Moving on to regulatory news, the FDA has granted accelerated approval to a new therapy for a rare form of cancer. This drug, developed by a leading biotech firm, targets a specific mutation found in certain types of tumors. The approval was based on promising clinical trial results showing significant tumor shrinkage in patients who had exhausted other treatment options. Accelerated approval is crucial as it allows patients earlier access to potentially life-saving treatments while further confirmatory trials are conducted. This decision underscores the agency's commitment to supporting innovation in oncology and addressing unmet medical needs. In another significant update, a major pharmaceutical company has reported positive phase 3 trial results for its new Alzheimer's drug. This medication aims to slow cognitive decline by targeting amyloid plaques in the brain, which are believed to play a role in the progression of Alzheimer's disease. The trial demonstrated statistically significant improvements in cognitive function among participants receiving the treatment compared to those on placebo. These findings could be transformative for Alzheimer's patients and their families, offering hope where few treatment options exist today. If approved, this drug could become one of the first disease-modifying therapies for Alzheimer's, marking a significant milestone in neurological research. Shifting our focus to vaccine development, scientists have made progress on a universal flu vaccine. This innovative approach seeks to provide broad protection against multiple strains of influenza with a single shot. By targeting conserved elements of the virus that do not change from year to year, this vaccine could potentially eliminate the need for annual flu shots. Early-stage trials have shown promising immune responses, and researchers are optimistic about advancing to larger-scale studies. The development of such a vaccine would represent a major leap forward in public health, reducing the burden of seasonal flu outbreaks worldwide. Turning our attention to industry trends, there is growing interest in artificial intelligence and machine learning applications within drug discovery. A recent report highlights how AI is being used to predict drug-target interactions and streamline clinical trial design. By leveraging large datasets and computational power, AI can identify potential drug candidates more efficiently than traditional methods. This technology is revolutionizing research and development pipelines by accelerating timelines and reducing costs, ultimately leading to quicker patient access to new therapies. As more companies invest in AI-driven approaches, it is anticipated that these technologies will become integral components of pharmaceutical innovation. Lastly, an update on sustainability within the industry: several companies are making strides toward reducing their environmental footprint through green chemistry initiatives and sustainable manufacturing practices. These efforts aim to minimize waste and energy consumption while ensuring safe production processes. As environmental concerns become increasingly prominent, adopting sustainable practices is not only socially responsible but also aligns with consumer expectations and regulatory requirements. The movement towards sustainability within pharma reflects broader global trends prioritizing eco-friendly innovations across industries. That concludes today's episode of Pharma Daily. Thank you for tuning in to stay informed about the latest advancements and insights shaping healthcare's future. Be sure to join us next time as we continue to explore groundbreaking developments across the pharmaceutical landscape. Until then, stay curious and keep pushing forward in your pursuit of knowledge and innovation!Support the show

Therapeutics, vaccines, will therapeutics replace vaccines?, was the Covid vaccine actually a therapeutic?, Robert F. Kennedy Jr., RFK Jr's mandate to put the HHS on war footing, Jeffrey Epstein, CRISPR, George Church, Editas Medicine, the Broad Institute, Boris Nikolic, Bill Gates, the manipulation of Gates by Epstein and Nikolic, Moderna, DARPA, ADEPT (Autonomous Diagnostics to Enable Prevention and Therapeutics), Moderna's lawsuit against BioNTech, Ralph Baric, University of North Carolina at Chapel Hill (UNC Chapel Hill), Remdesivir, Gildead Sciences, Jim Mellon, Thomas Cahill, Operation Warp Speed, the origins of the lockdowns in Bush II era in bio attack continuity of government planning, Total Information Aware (TIA), John Poindexter, Palantir, Poindexter's links to Palantir, the timing of Thiel's investment in Facebook, the time of Thiel and Mellon's biotech investments lining up with the launch of ADEPT, Epstein and neoliberalism, the ambiguous relationship between Israel and Russia, did Epstein target neolibs for Israel?, "transhumanism," cybernetics, Extropianism, World Economic Forum (Davos), the gutting of funding for mRNA vaccine research, RFK Jr.'s investments in therapeutics and CRISPR, RFK Jr.'s increased funding and deregulates therapeutics at HHS, RFK Jr.'s bilateral health agreements and their requirements that foreign countries turn over medical data to US, Palantir's aggressive move into medical data, medical data as the next gold rush, World Health Organization (WHO), wearables and RFK Jr.'s push for national adoption, biosurveillance and wearables, Steven Quay, Arc Institute, the lab leak hypothesis and China's variation on it, did the lab leak occur at UNC Chapel Hill?, were the US and PRC war gaming with the lockdowns?, MAGA's use of conspiracy theorists, how anti-vaxxers are being used for the therapeutics roll out, the takedown of Bill Gates, why the US will not rejoin the WHO without changes to the charter, the normalization of biowarfareResources:https://docs.google.com/document/d/1Gggqs2Ha08x6N7u-mZbmcGqXNHDopuFPNWkj0sTDZdE/edit?usp=sharingMusic by: Keith Allen Dennishttps://keithallendennis.bandcamp.com/ Hosted on Acast. See acast.com/privacy for more information.

Gene-editing researcher Raj Chari discusses how CRISPR technology is being used to study cancer, develop potential new treatments, and explore the challenges of bringing gene-editing therapies from the laboratory into clinical care.

In this episode of Lab Rats to Unicorns, John Flavin sits down with Dr. Kiran Musunuru, a cardiologist, geneticist, professor at the University of Pennsylvania, and leading expert in gene editing. Kiran's research spans cardiovascular, metabolic, and rare genetic diseases, with a focus on turning advances in human genetics and CRISPR into therapies that address the underlying causes of disease. He is also a co-founder of Verve Therapeutics and helped lead the development of a personalized gene-editing treatment for infant KJ Muldoon. Kiran traces the path that brought him to gene editing, from growing up with a cardiologist father and pursuing combined medical and scientific training to recognizing the potential of human genetics, stem cells, and eventually CRISPR. He explains how his willingness to adopt new technologies led his lab from early tools like zinc finger nucleases and TALENs to CRISPR, base editing, and prime editing. That progression ultimately opened the possibility of not simply treating symptoms, but making precise changes to DNA that could turn off disease-causing genes or repair genetic mutations at their source. Throughout the conversation, Kiran shares how experiments targeting the cholesterol gene PCSK9 led to the idea of a one-time treatment for cardiovascular disease and ultimately to the creation of Verve Therapeutics. He discusses his unexpected journey into entrepreneurship, Verve's progression into human trials and acquisition by Eli Lilly, and his return to academia to apply the same gene-editing platform to rare diseases. The episode culminates with the remarkable story of KJ, whose personalized base-editing therapy was designed and produced in roughly six months, as well as Kiran's larger vision for transforming one-off treatments into a scalable platform capable of reaching patients around the world.

Therapeutics, vaccines, Regeneron, will therapeutics replace vaccines?, the biotechnology industry, genetic engineering, Stanford, University of California at San Francisco (UCSF), the roll of the Bay area in biotech, advances in gene editing during the 1990s, mRNA and its links to therapeutics, Jesse Gelsinger, Bush II and bans on research, lipid nanoparticles (LNPs), the advent of synthetic biology, cell therapy, stem cells, embryonic stem cell controversy, CRISPR, CRISPR CaS9, Jennifer Dounda, Emmanuelle Cherpentier, Feng Zhang, Broad Institute, UC Berkeley, Intellia Therapeutics, CRISPR Therapeutics, Operation Warp Speed, Editas Medicine, Innovative Genomics Institute (IGI), Covid vaccines, why the Covid vaccines are more like a therapeutic, AI biotech, AlphaFold2, tech money piles into biotech post pandemic, Arc Institute, Vitalik Buterin, Big Pharma and its lack of involvement in therapeutics, Big Tech's entry into defense and healthcare, Peter Thiel, Thiel as the catalyst for modern therapeutic research, life-extension, Thiel's extensive investment in therapeutics and biotech, Jason Camm, Jim Mellon, Brexit, Thiel's lack of investment in CRISPRResourcesTrump on "miracle drugs":https://www.yahoo.com/news/article/trump-coronavirus-twitter-video-234914108.html?guccounter=1On the links between therapeutics and the Covid vaccineshttps://www.thelancet.com/journals/lancet/article/PIIS0140-6736(23)02444-3/fulltexthttps://pmc.ncbi.nlm.nih.gov/articles/PMC12179814/AI Biotechhttps://whatisbiotechnology.org/index.php/science/summary/aiBig Tech and AI biotechhttps://www.forbes.com/sites/richardnieva/2024/03/13/why-nvidia-google-and-microsoft-are-betting-billions-on-biotechs-ai-future/How funding for biotech has unfolded since the 2010shttps://www.fiercebiotech.com/biotech/how-healthy-exchange-ideas-rfk-jr-kicked-fdas-gene-therapy-pushThiel's Links to Biotechhttps://www.technologyreview.com/2015/03/16/168909/a-contrarian-in-biotech/https://sociallifemagazine.com/celebrities/bezos-thiel-longevity-investments/https://www.inc.com/jeff-bercovici/emerald-therapeutics-peter-thiel.htmlhttps://www.fiercebiotech.com/biotech/thiel-s-breakout-labs-fuels-four-new-life-science-companieshttps://alloytx.com/42-million-series-d-financing/https://www.wholesaleinvestor.com/epiaxis-therapeutics-peter-thiel-backed-peptilogics-enter-strategic-partnership/https://www.businessinsider.com/peter-thiel-funded-de-extinction-animal-resurrection-woolly-mammoth-2017-6https://www.sfgate.com/tech/article/synthego-after-raising-forced-bankrupcty-20331773.phpJason Camm's biohttps://www.berentx.com/companyMusic by: Keith Allen Dennishttps://keithallendennis.bandcamp.com/ Hosted on Acast. See acast.com/privacy for more information.

(0:00) Intro(01:10) Welcome to Biology Batch 1(01:43) The Vision and Curriculum Roadmap(02:01) DNA, CRISPR, Viruses and Python(04:17) Preparing Children for Scientific Research(06:30) Why Muslim Research Output Must Increase(07:26) The Real Purpose of Studying Biology(08:24) For Every Disease, Allah Created a Cure(09:30) Parents' Questions About Classes and Ages(12:32) Complete STEM and Homeschooling Vision(15:05) Source Code App and Student Development(18:51) Who Can Join This Biology Program?(20:30) Introduction to the Biology Curriculum(22:14) Why Traditional Biology Education Has Failed(23:15) Five Pillars of the Biology Program(24:40) Why Biologists Need Python(26:15) Connecting Biology with the Qur'an(27:32) The Vision Behind the Program(28:41) Critical Thinking and Scientific Intelligence(29:41) Learning Biology and Python from the Basics(30:23) Understanding Qur'anic Verses Through Biology(32:38) Creating Curiosity in Children(33:01) Concept-Based and Research-Based Learning(34:40) Weekly Assessments, AI and Bioinformatics(35:35) Complete Four-Year Curriculum Roadmap(37:00) Why Python Is Essential for Biological Data(38:41) From Basic Biology to Advanced Research(40:07) What Students Will Learn in Each Module(41:21) Machine Learning Explained Simply(42:10) Biotechnology, Research and Innovation(42:51) How Students Will Learn in Every Class(44:00) Major Research Projects Explained(44:13) Project 1: Computational Drug Discovery(45:54) Project 2: Protein Analysis and Simulation(47:26) Project 3: Predicting Antimicrobial Resistance(49:30) Final Project: CRISPR Gene Editing(51:18) Designing Targeted RNA with Python(53:16) Flexible Classes for Global Students(54:41) Discovering and Developing Muslim Talent(55:40) Changing the World from a Laptop(57:17) The Power of a Purpose-Driven Researcher(59:30) Weekly Assessments and Student Progress(01:01:17) Believe in Your Child's Potential(01:04:38) Can Students Compete Internationally?(01:08:38) MPhil-Level Knowledge for Children(01:11:29) Student Presentations and Daily Summaries(01:14:02) Assessments and Module Placement(01:16:16) Teacher Training and Quality Control(01:20:23) Why Every Week Must Count(01:25:15) Can University Students and Adults Join?(01:27:10) Why We Cannot Waste 20 Years(01:30:30) Biology, Chemistry and Research Intelligence(01:32:32) Homeschooling Guidance for Parents(01:35:25) Final Message and Closing Hosted on Acast. See acast.com/privacy for more information.

Wellness trends move fast, yet volume two of The Next Frontier Files proves some predictions age well. Revisiting year two of the show, host Jenn Trepeck tracks the guests who forecasted metabolic health, gut health, and body positivity long before they became mainstream conversations, and shows how precision medicine and permission became the defining threads of an entire year.Jenn Trepeck brings listeners of Salad with a Side of Fries a look back at the guest predictions that shaped the year two, August 2020 - August 2021, grading them against what really happened since.What You Will Learn in This Episode:✅ How telehealth and virtual training went from pandemic workaround to a permanent part of everyday healthcare✅ Why metabolic health and gut health became two of the most repeated topics in wellness over the following years✅ What guests predicted about wearable technology, gene editing, and the future of human biology✅ How body positivity and permission-based wellness reshaped the conversation around health and self-imageThe Salad With a Side of Fries podcast, hosted by Jenn Trepeck, explores real-life wellness and weight-loss topics, debunking myths, misinformation, and flawed science surrounding nutrition and the food industry. Let's dive into real-life wellness and weight loss, including drinking, eating out, and skipping the grocery store.TIMESTAMPS:00:00 Year two overview explains how telehealth shifted from workaround to permanent wellness trends infrastructure04:42 Chad Levy discusses virtual training, and Amy Marshall shares her perspective on Telehealth and Zoom technology06:55 Chris Burres introduces longevity as a frontier, and Natasa Billeci mentions AI and propels the precision medicine conversation08:49 Toxin exposure and cellular absorption enter the conversation through Tim James' product launch12:01 Corey Phelps highlights her views on meditation and breathwork12:58 Dr. Casey Means discusses metabolic health tools and using technology to return to basics15:53 Gut health gets its first mention by Mike Millner, predicting it is only 2% understood16:53 Dr. Anthony Balduzzi predicts gene therapy, CRISPR, and implantable technology merging with human biology18:25 Catharine Arnston embraces preventative medicine19:13 Sarah Nilsen expounds about CBD and cannabinoid research20:12 Jay Shifman comments on BMI and asks why is it still being used21:17 Sarah Malouf and Farah M. Green raise body positivity and the pressure to redefine beauty standards23:20 Jenn closes by tying the year's predictions together under precision and permissionKEY TAKEAWAYS:

Have you heard about the radioactive wolves in Chernobyl? Or the latest gene-editing tech that's curing rare diseases? Or that male birth control might be on the horizon? No?!Well, get ready, because while we've been busy living our lives, genomics has been moving – fast! Things that once read like science fiction are moving on over to the non-fiction section.This season on Nice Genes!, join Dr. Kaylee Byers as she engages in some big genomics breakthroughs – from personalized cancer treatments, to how our bodies react in space, to how animals adapt to the most extreme environments, and whether we can actually change how we age.It's a whole new gene-eration (if you will) of discoveries that you won't want to miss!New episodes every two weeks, starting September 8th. Make sure you follow Nice Genes! so you don't miss an episode!

Emotional support at the end of life. Thorny halachic questions about scientific medical breakthoughs. AI and the end of work.These are all part of the Rabbi Jason Weiner's daily routine.Rabbi Weiner is the senior rabbi and executive director of spiritual care at Cedars Sinai in Los Angeles. In this episode we cover:What a healthcare chaplain actually does, and how Rabbi Weiner fell into the role with almost no trainingThe hardest moments of sitting with grieving families, including an uplifting story that took nearly 20 years to find its endingHow Torah sources think about medical breakthroughs like CRISPR and GLP-1 drugsHis essay on AI and the end of work: if a machine takes your job, does it take your identity too?To read the full Tradition Online essay about AI and the end of work, click hereFind more from Rabbi Weiner at rabbiweiner.com, on YUTorah, on LinkedIn, or on Instagram at @rabbi_JW.Sign up for our newsletter to recieve unfiltered takes on work, Torah, family and more. Go to ShtarkTank.org and subscribe today.

BEST OF: After our “AILIEN The Final Card” show, it became apparent that the push to grant mass “amnesty” to every person and agency involved in black budget programs was a dangerous narrative gaining more traction by the day, and now compounded by an executive order from the White House titled “Launching the Genesis Mission.” This program seeks to support, along with the AI regulation moratorium of the BBB, the narrative that “America is in a race for global technology dominance in the development of artificial intelligence (AI).” The first section states: “the challenges we face require a historic national effort, comparable in urgency and ambition to the Manhattan Project that was instrumental to our victory in World War II.” But what suddenly changed? Have other countries cracked the AI egg entirely or has, as the UFO community suggests, they reverse engineered alien tech fully? Even so, a dangerous nationwide Manhattan Project should be a secret, not a public initiative. One part of the EO says the goal is to develop "AI-enabled predictive models, simulation models, and design optimization tools,” things that have been sold to the public over and over again, from climate change to pandemic models, but which have all been wrong. But if AI says something is true based on a model, it must be correct. However, if AI is merely saying what is most likely based on current actions, like a tarot reading, then if all current policies are designed for war then isn't that what we will get? Isn't that what Alex Karp of Palantir said would happen? And isn't “Genesis” also “skynet”?For those left waiting for something “big” to happen it will be disappointing to learn that it already has. Engineered smart/micro-dust is currently turning the world into a giant sensor, while Sam Altman of the Stargate Project, OpenAI, and the Orb, is now funding CRISPR-based embryo gene editing as the alterer-of-man.And to keep us entertained during this slow-burn apocalyptic invasion, we have KION, an AI-created K-pop star who's clearly created with all he best black goo moments from Taylor Swift, Lady Gaga, Billie Eilish, and the like. It all makes sense if the gift of “UFO technology” may in fact be a series of blueprints to build the alien mind on earth; the name KION, from various languages, translates to ancient-foundation-leader-possessed. In other words, Lovecraft's Old Ones once more. But IT is being sold as a sexy black goo princess. *The is the FREE archive, which includes advertisements. If you want an ad-free experience, subscribe below. 

THE STORY of Frankenstein and his monster can be read as a tale of daddy issues with catastrophic consequences. That's not quite how we see it.Joining us for a deeper dive into the tale of Frankenstein and his monster is our regular Iron and Myth crew: Dr. Judd Burton (BurtonBeyond.net), author of Interview With the Giant; Doug Van Dorn (DouglasVanDorn.com), author of Battle for the Bible's Truth: Genesis, Jesus, and the Second Century Plot to Deny the Messiah; and Brian Godawa (Godawa.com), best-selling author of Daniel: Exile in Babylon, the first novel in a trilogy about the life of Daniel.The tale of Frankenstein, over 200 years old, has continued to inspire countless adaptations and debates. Brian notes that the narrative encapsulates humanity's (and the angelic realm's) primal drive to create life. This inherent desire raises questions about the morality of creation and the responsibilities that come with it.One cannot discuss Frankenstein without acknowledging its biblical undertones. From the story of Genesis, where knowledge leads to the fall, to the cautionary tales of the Watchers in the Book of Enoch, there is a recurring theme of humanity overstepping its bounds. Doug emphasizes that Victor Frankenstein's actions mirror those of the Titans in Greek mythology, who faced dire consequences for their hubris. The parallels between Victor's ambition and the biblical figures reveal a cautionary warning about the pursuit of forbidden knowledge.Today, the themes of Frankenstein are more relevant than ever as we navigate the complexities of genetic engineering and artificial intelligence. The discussions around CRISPR technology and AI echo the dilemmas faced by Victor Frankenstein. As we strive to enhance human life, we must confront the ethical implications of our advancements. We discuss how the creation of autonomous life forms could lead to unintended consequences—much like those faced by Victor and his creation.Follow us!• X: @viewfrombunker (https://x.com/viewfrombunker) | @sharonkgilbert (https://x.com/sharonkgilbert) | @derekgilbert (https://x.com/derekgilbert)• Telegram: t.me/gilberthouse• Substack: gilberthouse.substack.com | sharonkgibert.substack.com• YouTube: @GilbertHouse (https://youtube.com/@gilberthouse) | @UnravelingRevelation (https://youtube.com/@unravelingrevelation)• Facebook.com/viewfromthebunker

The Counter Momentum of Spin, with Dr. Franco Musio – Dr. Li-Meng Yan examines how Chinese Communist Party influence shapes medical research, scientific collaboration, and US institutions. The discussion explores SARS-CoV-2 origins, cognitive warfare, Chinese students, Big Data manipulation, and the controversial CRISPR gene-editing case involving researcher He Jiankui while questioning ethics and national security...

Guest: Dr. Abdullah Khan is an Associate Professor of Tissue Engineering at the University of Oxford and a Group Leader at the MRC Weatherall Institute of Molecular Medicine. He discusses how his lab engineers complex human tissue models to study the cellular interactions that drive development, aging, and disease. He also explores how multi-organoid systems can model interactions between tissues such as the bone marrow and heart, and how these platforms could advance disease modeling, drug discovery, and preclinical research. Featured Products and Resources: Get a free wallchart on the derivation and applications of hPSCs. Subscribe to ESC & iPSC News to receive all of the latest research, news, jobs, and events in ESC & iPSC research. The Stem Cell Science Round Up Rescuing hPSC Differentiation – A chemical chromatin restoration approach reverses differentiation defects in human pluripotent stem cells, restoring their ability to generate diverse cell types and brain organoids. A Tumor Organoid Atlas – Patient-derived tumor organoids reveal cancer-specific gene dependencies and therapeutic vulnerabilities, providing a resource for advancing precision oncology. Mapping New Cancer Vulnerabilities – CRISPR screening of organoids and spheroids expands the Cancer Dependency Map, revealing cancer vulnerabilities and molecular subtypes missed by traditional cell lines. Building Better Cancer Models – A large collection of next-generation cancer models captures much of the genetic and epigenetic diversity of patient tumors, creating a resource for studying cancer biology and treatment response. Modeling Heart Valve Disease – Human iPSC-derived valve assembloid models heart valve development and reveals how mechanical forces and fluid flow shape valve formation and disease. Heart Valves in the Lab – Stem cell-derived 3D heart valve tissues recapitulate key features of valve maturation and provide a human platform for studying inflammation and calcific valve disease. Photo Reference: Courtesy of Dr. Abdullah Khan. Subscribe to our newsletter! Never miss updates about new episodes. Subscribe

What makes a bioweapon effective? What are researchers actually capable of creating in the lab? What pathogens are kept in storage? How realistic is a large scale catestrophic attack using a bioweapon? In this conversation I speak with Kevin Esvelt, who is an associate professor at the MIT Media Lab, where he leads the Sculpting Evolution Group in advancing biotechnology safely. Kevin was one of the pioneering researchers behind gene drive technology. In 2013, recognizing the potential dangers of the technology, he and his colleagues chose to break with scientific tradition by revealing their findings and calling for open discussion and safeguards before building the first CRISPR-based gene drive system and demonstrating reversibility in the laboratory. Kevin now focuses on accelerating beneficial advances while safeguarding biotechnology against mistrust and misuse. Projects include building catalytic platforms for directed evolution, pioneering new ways of developing ecotechnologies with the guidance of local communities, developing early-warning systems to reliably detect any catastrophic biological threat, applying cryptographic methods to enable secure and universal DNA synthesis screening, and advising policymakers on how best to mitigate global catastrophic biorisks. We discuss the state of the art in pathogen development, as well as the tools available to safegaurd humanity. ►Watch on Youtube: https://youtu.be/SLj8vwliQp0  ►You can find out more about Kevin's work here: https://www.sculptingevolution.org/kevin-m-esvelt ►Follow Kevin on X: @kesvelt  

On In The Market with Janet Parshall this week, Biochemist Dr. Fazale Rana discussed the pros and concerns of the new gene editing technology CRISPR. A former Muslim shared her journey to Christ and why we need to pray for Iranian believers who are facing increased persecution. Olivier Melnick from Shalom in Messiah ministries was back to address the ongoing attacks on Jews across the world and why popular accusations of colonization, occupation, apartheid and genocide by the Jews have no basis in history or truth. Dr. Sam Storms joined us for an important conversation about the exclusivity of the gospel and why Jesus is, was, and ever shall be the ONLY ways of salvation. He took us deep into John 14:6 & Romans 1:18-25 and explained why all of God’s word is focused on one goal: Salvation. The attack on efforts to lead people away from same-sex struggles is spreading, so Wayne Blakely shared with us a new documentary addressing this very serious issue and the ongoing attacks on religious freedom. It is time to put some of the biggest headlines of the week under the unflinching magnifying glass of God’s word.Become a Parshall Partner: http://moodyradio.org/donateto/inthemarket/partnersSee omnystudio.com/listener for privacy information.

Send us Fan MailEl nacimiento de la biología molecular en la década de 1970 vino de la mano de una gran promesa: curar enfermedades genéticas de manera rutinaria... y eventualmente resucitar a los dinosaurios. Esto último sigue en el dominio de la ciencia ficción, pero la terapia génica se alzó como la gran promesa terapéutica, una que se encontró con la tragedia en Estados Unidos y normativas más estrictas, solo para acabar dando la vuelta y generando otra tragedia en China, una que estuvo a punto de pasar desapercibida. Support the show

Metastatic osteosarcoma remains a major clinical challenge, highlighting the need to better understand the molecular mechanisms that drive disease progression. In this talk, Moreno will present the use of an in vivo CRISPR interference (CRISPRi) screen to identify genes that promote osteosarcoma progression. She will focus on KLF5, a transcription factor that emerged as a key regulator in our studies, and discuss its potential as a therapeutic target for osteosarcoma.Marta Roman Moreno, PhD, is a postdoc fellow in the Sweet-Cordero Lab at UCSF. She has a BSc in Biochemistry from the University of Granada in Spain, and an MSc and PhD in Biomedical Research from the University of Navarra (Spain). The key focus of her work is to define key regulators of metastasis in osteosarcoma and determine the vulnerabilities that can diminish the survival of metastatic cells. Using mouse models, cell lines derived from patient samples (PDXs) and pooled in vivo CRISPR screens, she has been able to identify several potential genetic vulnerabilities in the context of metastatic osteosarcoma.

In this week's episode, Blood editor Dr. James Griffin interviews Drs. George Goshua, Gerd Blobel, and Paul Kaminski on their latest articles published in Blood. Dr. Goshua elaborates on the background and then insights from "Haploidentical transplant, gene therapy, and standard care in sickle cell disease: a cost-effectiveness analysis". This analysis provides valuable guidance for clinicians, patients, and health systems as they consider treatment choices. However, as concluded in the accompanying Blood Commentary, the true measure of success is not which therapy “wins” the economic argument, but whether each patient receives the therapy best suited to their clinical needs and values. Then, Drs. Gerd Blobel and Paul Kaminski share "Dissecting polycomb complexes for enhanced fetal hemoglobin production", which utilizes a comprehensive CRISPR-based screen to interrogate the components of these repressive complexes and identified a single protein domain in EZH2, a subunit of PRC2, as a potential therapeutic target. They demonstrate that inhibition of the domain encoded by exon 14 of EZH2 selectively derepresses fetal hemoglobin expression, raising the possibility of developing drugs that specifically target this domain to treat hemoglobinopathies.

AI can now read DNA like language, generate working biological sequences, and help scientists identify disease-related mutations. Radical Numerics CEO Eric Nguyen explains how genome language models work, why his earlier model Evo helped scientists design CRISPR systems and bacteriophage genomes, and how the company's newer model, Omnii, combines DNA with RNA, proteins, and other biological signals. The conversation explores personalized medicine, gene therapy, AI-designed biological threats, “deepfake viruses,” and whether the same technology that creates new biology can also defend against it.Learn more about Radical Numerics: https://www.radicalnumerics.ai/

Christopher Mason, a geneticist and NASA investigator and author of The Next 500 Years: Engineering Life to Reach New Worlds, outlines a 500-year plan to enable human survival beyond Earth. Central to his vision is the deontogenic ethical framework, which asserts that humanity has a "genetic duty" to serve as guardians of life across the universe. To facilitate interstellar travel on generation ships, Mason proposes using advanced tools like CRISPR to edit human genomes and epigenomes to survive extreme environments. This includes adapting biological lessons from tardigrades for radiation resistance and bears for hibernation during long transit. He envisions "chloro-humans" capable of photosynthesis and humans who can synthesize their own essential vitamins. Beyond biological tweaks, Mason discusses ectogenesis (artificial uteruses) to manage human development during multi-generational journeys. While radical, Mason argues these modifications ensure "planetary liberty," allowing humans to inhabit worlds like Mars or Titan safely. (1)

This hour, Dr. Fazale Rana, from Reasons to Believe, will discuss gene-editing technologies such as CRISPR and how these advances are transforming medicine, giving scientists the ability to correct genetic disorders like cystic fibrosis and sickle cell anemia. But are they playing God? Then, you hear about an exciting on-line event being put together by Iran Alive ministries that take you beyond the headlines to give you keen insight into what it is like to live under a theocracy. Don’t miss a minute of this conversation.Become a Parshall Partner: http://moodyradio.org/donateto/inthemarket/partnersSee omnystudio.com/listener for privacy information.

Utah is in the spotlight — Mirror Lake Highway, the stunning 42-mile scenic byway through the Uinta Mountains, was just named the most beautiful road in the United States. We ask the chat what they think.  Then, a morning Memphis news anchor goes viral after falling asleep live on air. It's sparking a bigger conversation: should workplaces have sleep rooms?  Plus, scientists have used CRISPR gene editing to create two hypoallergenic beagles named Bailey and Alfie that don't trigger allergies. It's a breakthrough for millions of dog lovers — but could it steer people away from adopting shelter pets? And KFC responds after a man claims his popcorn chicken bucket came up short. We've got the TikTok and the corporate clapback. KSL Brightside streams live weekdays 12–3 PM. Watch the YouTube-exclusive live stream from 12–1 PM, then catch us on radio and YouTube from 1–3 PM.  

In this episode, ATLVets welcomes Ed You, a former FBI Supervisory Special Agent with more than 20 years of experience in counterterrorism, biodefense, and emerging technologies. With a background in biochemistry, molecular biology, cancer research, and national security, Ed has advised the FBI, HHS, the Office of the Director of National Intelligence, the White House, and the U.S. delegation to the Biological Weapons Convention.Drawing from decades of experience, Ed explains why biotechnology, artificial intelligence, and data are reshaping national security, economic competitiveness, and the future of innovation.Chapter Segment:00:00 – Welcome & Speaker Introduction02:20 – From Biochemist to FBI Special Agent04:20 – Biological Threats & National Security09:00 – Operation Warp Speed10:45 – The Global Biotech Race12:30 – Modern Biological Threats15:00 – AI, Data & Biotechnology18:45 – America's Innovation Challenge20:15 – The Value of Data22:30 – China & Strategic Competition26:30 – The Bioeconomy29:40 – Opportunities for Entrepreneurs33:00 – AI Beyond the Hype37:00 – Audience Q&A38:25 – Biomanufacturing & Supply Chains42:15 – Biotechnology & Global Influence44:30 – Preparing the Next Generation47:10 – CRISPR & Gene Editing49:55 – The Future of Biosecurity51:30 – Closing RemarksIf you enjoyed this conversation, be sure to like, subscribe, and share this episode with someone interested in leadership, national security, biotechnology, or emerging technologies.Have a question or perspective on the future of AI, biotech, or the bioeconomy? Leave it in the comments—we'd love to continue the discussion.

This Washington Post column by Monica Hesse argues that the return of Ted Lasso is timely because the character's defining strength, optimism, remains a rare and valuable trait in modern culture. The piece is less a TV review and more a reflection on why audiences connected with Ted in the first place and why they may need him again now. Scientists have successfully used CRISPR gene-editing technology to create what may be the world's first dogs specifically engineered to eliminate a major dog allergen, potentially opening the door to truly hypoallergenic pets in the future. Please Like, Comment and Follow 'Philip Teresi on KMJ' on all platforms: --- Philip Teresi on KMJ is available on the KMJNOW app, Apple Podcasts, Spotify, YouTube or wherever else you listen to podcasts. -- Philip Teresi on KMJ Weekdays 2-6 PM Pacific on News/Talk 580 AM & 105.9 FM KMJ | Website | Facebook | Instagram | X | Podcast | Amazon | - Everything KMJ KMJNOW App | Podcasts | Facebook | X | Instagram See omnystudio.com/listener for privacy information.

Environmental journalist, Michael Dulaney looks at viruses and bacteria that can move between bats, horses, seals, pigs, voles and even polar bears, and the conditions that lead to human infection.These diseases are known as zoonoses.Michael says climate change, urban sprawl, animal farming and even homelessness contribute to wild animals coming into ever closer contact with people, leading these illnesses to move from creatures to us.To understand how this process works, Michael has researched the volunteers dedicating their lives to conservation. He has camped out on a freezing Victorian night to try to catch ducks with a net shot from a cannon, to test them for bird flu. He has gone frog hunting in the jungles of Indonesia, and he's visited a suburban Melbourne apartment where a dedicated citizen gives up her master bedroom to a collection of injured flying foxes, while she sleeps in the spare room.Michael also explains how the curious case of Trench Fever fits into the zoonotic puzzle. It was found first in Edmonton, Canada in 2022, when patients developed a serious heart condition after they were given organs donated by homeless victims of the opioid crisis.Further informationSentinels: When diseases spread between animals and humans is published by Scribe.This episode was produced by Alice Moldovan. Conversations' Executive Producer is Nicola Harrison.This episode covers H5N1 bird flu, covid-19, pandemic, lockdown, flu, cat flu, swine flu, hendra virus, horse racing, horse trainer, fly by night bat clinic, Werribee poo ponds, necropsy, chicken farms, disease-proof pigs, PRRS, CRISPR, vaccines, vaccination, smallpox, pox virus, borealpox and northern red-backed vole.To binge even more great episodes of the Conversations podcast with Richard Fidler and Sarah Kanowski go the ABC listen app (Australia) or wherever you get your podcasts. There you'll find hundreds of the best thought-provoking interviews with authors, writers, artists, politicians, psychologists, musicians, and celebrities.

Guest: Nobel Laureate Dr. Shinya Yamanaka is the Director Emeritus of the Center for iPS Cell Research and Application (CiRA), President of the CiRA Foundation, Professor at Kyoto University, and Senior Investigator at the Gladstone Institutes. 20 years after the discovery of iPSCs, he discusses how his lab is advancing iPSC therapies toward the clinic while continuing to investigate the basic mechanisms underlying pluripotency, stem cell biology, and translation initiation. He also shares his vision for the future of regenerative medicine, the ethical challenges posed by emerging stem cell technologies, and the opportunities created by combining iPSC with advances such as CRISPR and organoids. Featured Products and Resources: Get a free wallchart on the directed differentiation of hPSCs. Subscribe to STEMCELL Sceince News to stay current with the latest research and news in the fields of immunology and cell biology. The Stem Cell Science Round Up Elephant iPS Cells – Researchers have generated the first induced pluripotent stem cells from Asian elephants, providing a new platform for conservation and disease research. Epigenetic Cell Counter – Intestinal stem cells use an epigenetic division-counting mechanism to precisely control cell fate decisions during tissue maintenance. Reversing Bone Marrow Aging – Long-term vitamin C supplementation partially reverses age-related changes in primate bone marrow and hematopoietic stem cell function. Human Heart Atlas – A comprehensive atlas of human cardiac organoids reveals how signaling molecules regulate heart function and identifies pathways linked to heart failure. Photo Reference: Courtesy of Dr. Shinya Yamanaka. Subscribe to our newsletter! Never miss updates about new episodes. Subscribe

>p>Broadcast from KSQD, Santa Cruz on 7-30-2026: A type of coffee brewed from beans that have been altered by passage through the digestive track of civet cats is a delicacy in Southeast Asia. A Scientific Reports paper using gas chromatography analyzed Kopi Luwak (civet-processed coffee beans) versus fresh-picked beans, finding elevated caprylic and capric acids that carry the characteristic flavor notes found in dairy products. Dr. Manuel Esteller sampled and tested the blood, saliva, urine, and stool of the oldest human Maria Branyas Morera, who died last year at 117. Despite exceptionally short telomeres, she carried anti-inflammatory genetic variants seen in long-lived dogs, worms, and flies, and had unusually high Bifidobacterium levels—likely boosted by her three-daily-servings-of-yogurt habit. Dr. Dawn defends sunscreen use against Environmental Working Group scare campaigns, noting that concerns about absorption of sunscreen ingredients into blood remain theoretical while sunburn's melanoma link is well-established. She argues that a badly sunburned toddler starts a clock that can produce melanoma by the late teens. The FDA advisory committee is reviewing certain short amino acid chains popularly known as "peptides" for potential compounding-pharmacy production, covering proposed to treat ulcerative colitis, wound healing, insomnia, insulin resistance, migraines, and osteoporosis. Dr. Dawn flags that five to seven committee members have industry conflicts of interest, but argues that even flawed approval is preferable to the current gray market, where analysis shows vials contain only 4-28% of labeled content along with endotoxin and toluene contamination. She proposes surveillance tracking of prescribed peptides to catch adverse effects early, citing a foreign melanocortin nasal spray tanning product that caused rare nasal melanomas as a cautionary example. Utah State biochemists working with the Cas12a2 CRISPR enzyme discovered that instead of behaving as a precise gene-editor like Cas9, it goes into an indiscriminate DNA-shredding mode after recognizing its target RNA. By programming it to recognize RNA sequences uniquely activated in cancer cells (embryonic-development genes that shouldn't be running in adults), researchers destroyed only the cancer cells in tissue culture, potentially offering a way to eliminate small metastases without healthy tissue toxicity. Cancer patients who received a COVID-19 mRNA vaccine within 100 days of starting immune checkpoint inhibitor therapy showed dramatically improved outcomes, with median survival in advanced lung cancer rising from 20 to 37 months. Non-mRNA vaccines (flu, pneumonia) showed no such benefit. Lab work suggests the mRNA triggers type-1 interferon release that activates tumor-infiltrating immune cells and drives them to lymph nodes to train other immune cells against the tumor. Researchers redesigned a CD40 agonist antibody to bind multiple receptors simultaneously by clustering with a second antibody, stretching the cell surface and triggering a powerful immune response. In a 12-patient trial, injecting one tumor caused all tumors to shrink in six patients and produced complete remission in two—including a melanoma patient with dozens of leg tumors and a metastatic breast cancer patient whose lung and liver tumors resolved after skin injection. Two small trials of CAR natural killer cells—engineered like CAR T-cells but derived from donor umbilical cord blood and thus potentially available off-the-shelf—showed remarkable results in autoimmune disease. All 27 systemic lupus patients targeting the CD19 protein on autoantibody-producing cells showed improvement, with some remaining in remission at nearly two years. A single Shanghai patient with systemic sclerosis showed restoration of normal skin and blood vessel structure. A paradox has emerged in advanced prostate cancer: while blocking testosterone halts early tumor growth, cancer cells eventually adapt to low-androgen conditions such that flooding tissues with testosterone in advanced disease can actually halt tumor progression by triggering cellular redifferentiation. Separately, Dr. Dawn reviews conflicting evidence on Parkinson's risk from androgen deprivation therapy, singling out enzalutamide (Xtandi) as the most concerning drug due to blood-brain barrier penetration, and recommending darolutamide as the safest alternative with matching prostate efficacy but minimal CNS entry.

¿Qué ocurre cuando una terapia genética experimental pasa del laboratorio a un paciente humano antes de que sepamos realmente si es segura? En este video analizamos el caso de una niña de 6 años en China que murió después de recibir una terapia génica experimental basada en edición genética, un caso que ha abierto preguntas extremadamente serias sobre medicina genética, bioética, investigación clínica, seguridad de las terapias génicas y los límites de la ciencia.El caso ocurrió el 24 de marzo de 2025, cuando médicos y científicos intentaron tratar a una niña cuya enfermedad estaba relacionada con una mutación genética que afectaba el desarrollo de su cerebro. El equipo desarrolló un base editor, una herramienta de edición genética diseñada específicamente para corregir la mutación, y utilizó virus modificados como vehículo para transportar las instrucciones hasta las células cerebrales. La terapia había mostrado resultados prometedores en modelos animales, incluyendo ratones y primates, y los padres decidieron asumir los riesgos con la esperanza de evitar una vida marcada por una discapacidad grave.Pero el tratamiento tuvo un desenlace devastador. Después de recibir la terapia génica, la niña desarrolló fiebre y posteriormente signos de daño renal, falleciendo aproximadamente una semana después. Una investigación de Science y Retraction Watch, basada en el trabajo del periodista Brendan Borell, examinó el caso y las circunstancias que rodearon el tratamiento. De acuerdo con un informe hospitalario, una de las explicaciones más probables fue una respuesta inmunitaria grave contra los virus utilizados para administrar el editor genético.El caso plantea preguntas fundamentales: ¿cuándo es ético probar una terapia genética en un niño? ¿Qué significa realmente que un tratamiento haya funcionado en ratones y monos? ¿Cuánta evidencia necesitamos antes de administrar una tecnología de edición genética experimental a un ser humano? ¿Los padres recibieron información suficiente sobre los riesgos? Y, quizá la pregunta más incómoda, ¿qué ocurre cuando la esperanza de una cura se encuentra con una tecnología que todavía no comprendemos completamente?En el video hablamos de terapia génica, edición genética, CRISPR, base editing, base editors, vectores virales, terapia génica in vivo, enfermedades genéticas, neurogenética, ensayos clínicos, modelos animales, seguridad biológica, bioética, consentimiento informado y medicina experimental. También explicamos cómo funcionan los editores de bases, por qué los virus pueden utilizarse para transportar herramientas genéticas hasta las células y por qué una terapia que parece segura en animales puede comportarse de manera completamente diferente en un paciente humano.Además, analizamos las preguntas que han surgido alrededor de la investigación científica que precedió al tratamiento, incluyendo dudas sobre la seguridad observada en primates, la transparencia sobre la muerte de la paciente y la responsabilidad de los investigadores y de las revistas científicas al comunicar resultados de terapias experimentales. El caso también abre un debate sobre conflictos de interés, regulación de la investigación médica, responsabilidad científica y los límites de la innovación biomédica.La edición genética promete revolucionar el tratamiento de enfermedades que durante décadas parecían incurables. CRISPR y tecnologías como el base editing podrían algún día corregir directamente las mutaciones responsables de enfermedades humanas. Pero este caso nos recuerda que entre demostrar que una tecnología funciona en un laboratorio y demostrar que es segura para una persona existe un abismo.Porque cuando estamos hablando de ciencia experimental, el fracaso no significa simplemente que un experimento no funcionó. A veces significa que alguien paga el precio. Y la pregunta es cuánto riesgo estamos dispuestos a aceptar en nombre de una posible cura.

Part 2! Dr. Eric Jaffe returns to actually treat the cancer this time: why radiation is basically catching your kid smoking and making him finish the carton, how CRISPR turns your own T cells into an assassin squad, and why oncolytic viruses are just Jurassic World Dominion for tumors. Haven't heard Part 1 yet? Start there or you'll be lost. Mentioned: CAR-T therapy RAS inhibitor drugs Oncolytic viruses mRNA cancer vaccines Red Queen hypothesis Cancer-sniffing dogs Are you an expert in something and want to be on the show? Apply here! Please support the show on Patreon! You get ad-free episodes, early episodes, and other bonus content! https://www.patreon.com/seriouspod

Send us Fan MailPediatric cancer is a gut punch most people can't look at for long, and that discomfort has a cost. We sit down with Dr Dean Lee, Professor of Pediatrics at The Ohio State University and Nationwide Children's Hospital, to talk about why kids' cancer research is still massively underfunded and why community-driven giving is not a feel-good extra. It's often the only way the next breakthrough gets its first chance.We unpack the hard truth behind the pediatric cancer funding gap: fewer patients means fewer commercial incentives, and “trickle-down” solutions from adult oncology don't always fit the diseases kids actually face. Dean explains why childhood cancer can be oddly invisible day to day, even though it remains a leading cause of death in children outside of accidents, and why foundations like Cancer Free Kids step in to fund the science that government grants won't touch early on.Then we get into hope with specifics. Dean walks us through what's changing in cancer immunotherapy and cellular therapy, including why CAR T cell therapy was a game-changer in leukemias and lymphomas and why solid tumors have been so much harder. We also talk about what pilot grants really do, how a $50,000 award can create the preliminary data needed for major funding, and a real example involving CRISPR and natural killer cell research that grew into a much bigger research platform.Join us for the third annual Little Legends Lemonade:

View the Show Notes Page for This Episode Become a Member to Receive Exclusive Content Sign Up to Receive Peter's Weekly Newsletter In this episode of The Drive, Peter explores how seemingly obscure basic science discoveries have laid the foundation for some of the most important medical breakthroughs of the past half century. Rather than focusing on the clinical applications of modern therapies, he traces the fascinating stories behind the scientists, experiments, and unexpected discoveries that ultimately led to transformative drug classes, revealing how groundbreaking advances often emerge from research with no obvious clinical goal. Through these historical case studies, Peter provides a new perspective on the unpredictable path of medical innovation and makes the case for why investing in basic scientific research remains essential for driving the next generation of life-changing therapies. We discuss: The discovery of green fluorescent protein (GFP): how curiosity about glowing jellyfish transformed modern biology [2:30]; Why basic research and nature's biological innovations are the foundation of medical progress [10:45]; The discovery of statins: how fungi provided the blueprint for cholesterol-lowering drugs [15:15]; From snake venom to ACE inhibitors: the discovery of a cornerstone therapy for cardiovascular disease [21:00]; From Yellowstone hot springs to PCR: how Thermus aquaticus transformed modern biology and medicine [28:00]; The discovery of CRISPR: from salt flats to gene editing and genetic medicine [37:15]; The discovery of GLP-1 receptor agonists: from Gila monster venom to a new era in metabolic medicine [47:30]; Why curiosity-driven basic research is essential for the future of medical innovation [54:15]; and More. Connect With Peter on Twitter, Instagram, Facebook and YouTube

THE STORY of Frankenstein and his monster can be read as a tale of daddy issues with catastrophic consequences. That's not quite how we see it.  Joining us for a deeper dive into the tale of Frankenstein and his monster is our regular Iron and Myth crew: Dr. Judd Burton (BurtonBeyond.net), author of Interview With the Giant; Doug Van Dorn (DouglasVanDorn.com), author of Battle for the Bible's Truth: Genesis, Jesus, and the Second Century Plot to Deny the Messiah; and Brian Godawa (Godawa.com), best-selling author of Daniel: Exile in Babylon, the first novel in a trilogy about the life of Daniel. The tale of Frankenstein, over 200 years old, has continued to inspire countless adaptations and debates. Brian notes that the narrative encapsulates humanity's (and the angelic realm's) primal drive to create life. This inherent desire raises questions about the morality of creation and the responsibilities that come with it. One cannot discuss Frankenstein without acknowledging its biblical undertones. From the story of Genesis, where knowledge leads to the fall, to the cautionary tales of the Watchers in the Book of Enoch, there is a recurring theme of humanity overstepping its bounds. Doug emphasizes that Victor Frankenstein's actions mirror those of the Titans in Greek mythology, who faced dire consequences for their hubris. The parallels between Victor's ambition and the biblical figures reveal a cautionary warning about the pursuit of forbidden knowledge. Today, the themes of Frankenstein are more relevant than ever as we navigate the complexities of genetic engineering and artificial intelligence. The discussions around CRISPR technology and AI echo the dilemmas faced by Victor Frankenstein. As we strive to enhance human life, we must confront the ethical implications of our advancements. We discuss how the creation of autonomous life forms could lead to unintended consequences—much like those faced by Victor and his creation. Follow us! X: @viewfrombunker | @sharonkgilbert | @derekgilbertTelegram: t.me/gilberthouseSubstack: gilberthouse.substack.com | sharonkgibert.substack.comYouTube: @GilbertHouse | @UnravelingRevelationFacebook.com/viewfromthebunker Thank you for making our Build Barn Better project a reality! The building has HVAC, a new floor, windows, insulation, ceiling fans, and an upgraded electrical system! We truly appreciate your support. If you are so led, you can help out at www.GilbertHouse.org/donate. Download our free app! This brings all of our content directly to your smartphone or tablet. Best of all, we'll never get canceled from our own app! Links to the app stores for iOS, iPadOS, Android, and Amazon Kindle Fire devices are at www.GilbertHouse.org/app. Please join us each Sunday for the Gilbert House Fellowship, our weekly Bible study podcast. Log on to www.GilbertHouse.org for more details. JOIN US IN ISRAEL (NOTE NEW DATES)! We will tour the Holy Land October 24–November 3, 2027 with an optional three-day extension to Jordan. For more information, log on to GilbertHouse.org/travel. Special offers on our books and DVDs: www.gilberthouse.org/store. Discuss these topics at the VFTB Facebook page (facebook.com/viewfromthebunker) and check out the great podcasters at the Fringe Radio Network (Spreaker.com/show/fringe-radio-network)!

The "man-moulders of the new age" vs. Imago Dei. __________ Partner with thousands of others in supporting The Colson Center by visiting colsoncenter.org/cornerstone.